US Stock Insider Trading | CONMED Discloses One Insider Transaction on March 10

K-LinePoet · 2026-03-23T01:51:06+00:00

CONMED executive Lalomia Brent sold 26 shares at $39.90 per share on March 6, 2026, for a total transaction value of $1,037.40. The company specializes in minimally invasive surgical instruments and equipment, dedicated to improving surgical quality and patient care.

K-LinePoet

2026-03-23 01:51:06

Abstract generation in progress

On March 10, 2026, CONMED (CNMD) disclosed one insider transaction. Executive Lalomia Brent sold 26 shares on March 6, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 10, 2026	Executive	Lalomia Brent	March 6, 2026	Sell	26	39.90	1,037.40
January 8, 2026	Executive	Lalomia Brent	December 31, 2025	Buy	31	40.60	1,284.02
November 24, 2025	Executive	Glaze Richard	November 21, 2025	Sell	257	41.21	$10,600
November 21, 2025	Executive	Glaze Richard	November 20, 2025	Sell	118	40.63	4,794.34
November 7, 2025	Executive	Garner Todd W	November 6, 2025	Sell	3,500	43.00	$150,500
November 5, 2025	Executive	Foust Hollie K	November 4, 2025	Sell	1,114	45.71	$50,900
November 3, 2025	Executive	Garner Todd W	October 31, 2025	Sell	2,164	44.00	$95,200
September 15, 2025	Director	Farkas Charles	September 12, 2025	Sell	1,103	53.54	$59,000
September 15, 2025	Director	Farkas Charles	September 12, 2025	Sell	897	53.51	$48,000
May 30, 2025	Director	Farkas Charles	May 29, 2025	Buy	1,000	55.70	$55,700

[Company Information]

CONMED Corporation was incorporated in 1970 under New York State law and became a Delaware corporation in May 2020. CONMED is a medical technology company focused on surgical instruments and devices used in minimally invasive surgery and monitoring. The company’s products are primarily used by surgeons and specialists across various fields including orthopedics, general surgery, obstetrics and gynecology, neurosurgery, and gastroenterology. The company’s main goal is to improve surgical outcomes and patient care through the development of innovative medical devices, enhancements of existing products, and new technologies, while reducing risks, trauma, costs, and surgical time. The company believes that by achieving these objectives, it can enhance its forecasting ability, meet customer needs and market opportunities, and deliver substantial returns to shareholders.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.